Why the UT Southwestern Medical Center is Enrolling Cancer Patients in Phase III TIGeR-PaC Clinical Trial from RenovoRx

UT Southwestern Medical Center and RenovoRx
RenovoRx Inc (RNXT) announced that the University of Texas (UT) Southwestern Medical Center is now enrolling pancreatic cancer patients in the open label, randomized Phase III TIGeR-PaC clinical trial.

The study is investigating RenovoGem, which utilizes RenovoRx’s proprietary therapy platform, Trans-Arterial Micro-Perfusion (TAMPä), to provide improved . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.